PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

European Pharmaceutical Review

DECEMBER 19, 2022

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. For this reason, a unique ‘abridged’ procedure was introduced to provide a specific regulatory pathway for biosimilars in the EU.

Medicine 52

Medicine Biopharma Safety Food 52

Pharmaceutical Representative Training

JANUARY 29, 2025

These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition.

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Marketing Physicians Biopharma 52

Clarivate

JULY 31, 2023

The migration of these products and services into the Clarivate portfolio further bolster solutions that support pharmacovigilance medical literature monitoring, patent research, systematic review literature searches, MDR literature review searches, as well as competitive and business intelligence research.

Healthcare 52

Healthcare Healthcare Safety Competition 52

Clarivate

OCTOBER 19, 2023

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects).

Networking 59

Networking Consulting Safety Side effects 59

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). Expect some provider practices to research using alternative treatments not subject to price negotiations for their new patients, assuming comparable efficacy, safety, and tolerability (e.g.,

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

DECEMBER 26, 2023

The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population. million for Hemgenix [AAV5-hFIX-Padua]). million for Hemgenix [AAV5-hFIX-Padua]).

Manufacturing 98

Manufacturing Safety Patients Competition 98

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. Hutchmed´s fruquintinib is a highly selective and potent oral inhibitor of VEGFR1-3. months; HR: 0.321, P<0.001).

Marketing 52

Marketing Safety Patients Competition 52

Clarivate

OCTOBER 7, 2021

What’s new from ESMO: Interim efficacy and safety analysis from the randomized KEYNOTE-716 study showed that the trial met its primary endpoint of RFS, with patients receiving Keytruda presenting an RFS of 90.5% This novel antibody-drug conjugate (ADC)ADC faces much competition, should it be approved. at 12-months compared to 83.1%

Patients 91

Patients Safety Marketing Physicians 91

Clarivate

DECEMBER 1, 2021

Treatment cost and compliance are key factors in sustaining effective long-term disease management, a powerful new oral option could be more widely accepted than the injectable competition and rapidly gain traction in the market, especially among primary care physicians. Contributors. Circulation 2021; 144(suppl1): LBS.05. Perin EC, et al.

Patients 52

Patients Safety Management Marketing 52